Hey this is interesting news i came across. I hope its true.
Clinical trials for new antibiotic on in India
Venus Remedies Ltd., a mid-size pharmaceutical company in India, is conducting advanced clinical trials for a new formulation that aims to provide total solution to the treatment of acute and sometimes fatal infections caused by multi resistant species. The new formulation, a fixed dose combination drug of latest generation Cephalosporin with an Amino-glycoside, has been developed by the company?s research and development wing.
Venus initiated multi-centered phase III clinical trials after receiving the go-ahead from the Drug Controller General of India (DCGI). According to Venus Remedies, the new formulation, which will be used to treat life-threatening infections caused by multi resistant P aeruginosa or Acinetobacter species, will be ready for commercial launch by December 2005.
Infections with the bacteria P aeruginosa are a major cause of ill-health and mortality in patients suffering from cystic fibrosis?a lethal disease affecting the respiratory system, digestive system, endocrine system, and reproductive system. Acinetobacter, meanwhile, causes hospital-acquired infections including skin and wound infections, pneumonia, meningitis and urinary tract infection. A recent spurt of Acinetobacter related infections and deaths in UK hospitals indicates that the bacteria has become resistant to common antibiotics.
Venus? antibiotic formulation provides a broad coverage of bactericidal activity and potential synergic effects to minimize the development of resistance during treatment with a drug-resistant bacterium. If the Phase III clinical trials are successful, the remedy will be a boon for people suffering from cystic fibrosis, for which there is no defined cure till date, as this would help treat chronic bronchitis and other pulmonary infections.
June 17, 2005 in Clinical trials, Cystic Fibrosis | Permalink
TrackBack
TrackBack URL for this entry:
http://www.typepad.com/t/trackback/2665070
Listed below are links to weblogs that reference Clinical trials for new antibiotic on in India :
Clinical trials for new antibiotic on in India
Venus Remedies Ltd., a mid-size pharmaceutical company in India, is conducting advanced clinical trials for a new formulation that aims to provide total solution to the treatment of acute and sometimes fatal infections caused by multi resistant species. The new formulation, a fixed dose combination drug of latest generation Cephalosporin with an Amino-glycoside, has been developed by the company?s research and development wing.
Venus initiated multi-centered phase III clinical trials after receiving the go-ahead from the Drug Controller General of India (DCGI). According to Venus Remedies, the new formulation, which will be used to treat life-threatening infections caused by multi resistant P aeruginosa or Acinetobacter species, will be ready for commercial launch by December 2005.
Infections with the bacteria P aeruginosa are a major cause of ill-health and mortality in patients suffering from cystic fibrosis?a lethal disease affecting the respiratory system, digestive system, endocrine system, and reproductive system. Acinetobacter, meanwhile, causes hospital-acquired infections including skin and wound infections, pneumonia, meningitis and urinary tract infection. A recent spurt of Acinetobacter related infections and deaths in UK hospitals indicates that the bacteria has become resistant to common antibiotics.
Venus? antibiotic formulation provides a broad coverage of bactericidal activity and potential synergic effects to minimize the development of resistance during treatment with a drug-resistant bacterium. If the Phase III clinical trials are successful, the remedy will be a boon for people suffering from cystic fibrosis, for which there is no defined cure till date, as this would help treat chronic bronchitis and other pulmonary infections.
June 17, 2005 in Clinical trials, Cystic Fibrosis | Permalink
TrackBack
TrackBack URL for this entry:
http://www.typepad.com/t/trackback/2665070
Listed below are links to weblogs that reference Clinical trials for new antibiotic on in India :